Skip to main content

Diagnostic accuracy of the Xpert® MTB/RIF cycle threshold level to predict smear positivity: a meta-analysis

Buy Article:

$34.78 + tax (Refund Policy)

SETTING: Xpert® MTB/RIF is the most widely used molecular assay for rapid diagnosis of tuberculosis (TB). The number of polymerase chain reaction cycles after which detectable product is generated (cycle threshold value, CT) correlates with the bacillary burden.
OBJECTIVE To investigate the association between Xpert CT values and smear status through a systematic review and individual-level data meta-analysis.
DESIGN: Studies on the association between CT values and smear status were included in a descriptive systematic review. Authors of studies including smear, culture and Xpert results were asked for individual-level data, and receiver operating characteristic curves were calculated.
RESULTS: Of 918 citations, 10 were included in the descriptive systematic review. Fifteen data sets from studies potentially relevant for individual-level data meta-analysis provided individual-level data (7511 samples from 4447 patients); 1212 patients had positive Xpert results for at least one respiratory sample (1859 samples overall). ROC analysis revealed an area under the curve (AUC) of 0.85 (95%CI 0.82–0.87). Cut-off CT values of 27.7 and 31.8 yielded sensitivities of 85% (95%CI 83–87) and 95% (95%CI 94–96) and specificities of 67% (95%CI 66–77) and 35% (95%CI 30–41) for smear-positive samples.
CONCLUSION: Xpert CT values and smear status were strongly associated. However, diagnostic accuracy at set cut-off CT values of 27.7 or 31.8 would not replace smear microscopy. How CT values compare with smear microscopy in predicting infectiousness remains to be seen.

Keywords: Xpert; cycle threshold value; diagnosis; systematic review

Document Type: Research Article

Affiliations: 1: Centre for Chronic Immunodeficiency, Division of Infectious Diseases, Department of Internal Medicine II, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany 2: London School of Hygiene & Tropical Medicine, London, UK 3: National TB Reference Laboratory, National Centre of Phthisiology, Bishkek, Kyrgyzstan 4: Centre of Excellence for Research in AIDS, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, Centre for International Health, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand 5: Division of Infectious Disease, Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA 6: Synlab MVZ Gauting, Institute of Microbiology and Laboratory Medicine, World Health Organization Supranational Reference Laboratory of Tuberculosis, Gauting, Germany 7: Lung Infection and Immunity Unit, Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa 8: Department of Infectious Diseases, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile 9: Centre for International Health, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand 10: Foundation for Innovative New Diagnostics, Geneva, Switzerland 11: Laboratoire de Bactériologie-Hygiène, Centre Hospitalier Universitaire, Université de Lille-Nord de France, Unité Mixte de Recherche 8204, F-59021, Institut National de la Santé et de la Recherche Médicale U1019, Lille, France 12: Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA 13: Synlab MVZ Gauting, Institute of Microbiology and Laboratory Medicine, World Health Organization Supranational Reference Laboratory of Tuberculosis, Gauting, Germany, Department of Medicine, Imperial College London, UK 14: Mbeya Medical Research Centre, National Institute for Medical Research, Dar es Salaam, Tanzania 15: Celal Bayar University Faculty of Medicine, Department of Medical Microbiology, Manisa, Turkey 16: Regional Mycobacteria Reference Center, Hospital Universitario Central de Asturias, Oviedo 17: Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Biomedical Research Institute of Lleida, Lleida, Spain 18: Microbiology Unit, Department of Laboratory Medicine, National University Hospital, Singapore 19: Department of Science & Technology/National Research Foundation of Excellence for Biomedical Tuberculosis Research, and South African Medical Research Council Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa, National Reference Laboratory for Mycobacteria, FZ Borstel, Germany

Publication date: May 1, 2017

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
-